Hepatocellular Carcinoma Epidemiology

Key Highlights

 

• According to Surveillance, Epidemiology, and End Results (SEER), in the US, the incidence rate of Hepatocellular Carcinoma and Intrahepatic bile duct cancer was 9.0 per 100,000 which is estimated to be around 42,230 new diagnosed cases in 2021 and the mortality rate was 6.6 per 100,000 per year and the 5-year survival rate was 20.3%. Of them, the stage wise incident cases of Hepatocellular Carcinoma and intrahepatic bile duct cancer was Localized (45%), Regional (26%), Distant (18%), and Unknown (11%).

 

• Hepatocellular Carcinoma epidemiology is segmented as Total Incident Cases of Hepatocellular Carcinoma, Stage-wise Patients of Hepatocellular Carcinoma, and Total Treated Cases of Hepatocellular Carcinoma] in the Hepatocellular Carcinoma epidemiology report.

 

Request for unlocking CAGR of Hepatocellular Carcinoma Epidemiology

 

DelveInsight's ‘Hepatocellular Carcinoma Epidemiology Forecast — 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Hepatocellular Carcinoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Study Period: 2021-2034

 

Hepatocellular Carcinoma Epidemiology Disease Understanding

The DelveInsight’s Hepatocellular Carcinoma market report gives a thorough understanding of Hepatocellular Carcinoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Hepatocellular Carcinoma (HCC) defined as a liver tumor not eligible for local therapies given the extent of disease or liver tumors that recurred after local therapies. Patients with advanced HCC usually have significant underlying liver disease which is associated with poor tolerability to systemic chemotherapy.

 

The cancer may have spread to nearby lymph nodes and/or to distant sites within the body. Hepatocellular Carcinoma doesn't often metastasize, but when it does, it's most likely to spread to the lungs and bones. These cancers are widespread, they cannot be removed with surgery.

 

Signs and symptoms are not always directly related to the stage of the cancer, the effects of disease is highly individualized for each person and following are some of the symptoms occurred in individuals Gynecomastia, Erythrocytosis, High cholesterol, Hypercalcemia, Hypoglycemia.

 

Hepatocellular Carcinoma Diagnosis

Tests and procedures used to diagnose HCC include blood tests and liver tissue biopsy. Some of the tests and procedures used to diagnose Hepatocellular Carcinoma, such as CT scan and MRI,  are also used in the staging process. A positron emission tomography (PET) scan may also be used: PET scan, which is a procedure used to find malignant tumor cells in the body.

 

Hepatocellular Carcinoma Epidemiology

The Hepatocellular Carcinoma epidemiology section provides insights about historical and current Hepatocellular Carcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• According to Surveillance, Epidemiology, and End Results (SEER), in the US, the incidence rate of Hepatocellular Carcinoma and Intrahepatic bile duct cancer was 9.0 per 100,000 which is estimated to be around 42,230 new diagnosed cases in 2021 and the mortality rate was 6.6 per 100,000 per year and the 5-year survival rate was 20.3%. Of them, the stage wise incident cases of Hepatocellular Carcinoma and intrahepatic bile duct cancer was Localized (45%), Regional (26%), Distant (18%), and Unknown (11%).

 

• The disease epidemiology covered in the report provides historical as well as forecasted Hepatocellular Carcinoma epidemiology [segmented as Total Incident Cases of Hepatocellular Carcinoma, Stage-wise Patients of Hepatocellular Carcinoma, and Total Treated Cases of Hepatocellular Carcinoma] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

 

Country Wise- Hepatocellular Carcinoma Epidemiology

This section provides glimpse of the Hepatocellular Carcinoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

KOL- Views

To keep up with the current Hepatocellular Carcinoma patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Hepatocellular Carcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

 

Learn how the therapeutic market will evolve and grow in the coming years: Hepatocellular Carcinoma Market
 

Scope of the Hepatocellular Carcinoma Epidemiology Report

• The report covers the descriptive overview of Hepatocellular Carcinoma, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of Hepatocellular Carcinoma
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Hepatocellular Carcinoma, Stage-wise Patients of Hepatocellular Carcinoma, and Total Treated Cases of Hepatocellular Carcinoma

 

Hepatocellular Carcinoma Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatocellular Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hepatocellular Carcinoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Hepatocellular Carcinoma Report Insights

• Patient Population
• Therapeutic Approaches

 

Hepatocellular Carcinoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Hepatocellular Carcinoma Epidemiology Segmentation

 

Hepatocellular Carcinoma Report Assessment

• Disease Understanding
• Current Diagosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Hepatocellular Carcinoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Hepatocellular Carcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Hepatocellular Carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Hepatocellular Carcinoma?
• Out of all 7MM countries, which country would have the highest incident population of Hepatocellular Carcinoma during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Hepatocellular Carcinoma Disease market
• To understand the future market competition in the Hepatocellular Carcinoma Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Hepatocellular Carcinoma Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Hepatocellular Carcinoma Disease market
• To understand the future market competition in the Hepatocellular Carcinoma Disease market